Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure

Transplantation Reviews

Volumn 25, Issue 2, 2011, Pages 47-57

  Tett, Susan E ^a   Saint Marcoux, Franck ^b,c,d   Staatz, Christine E ^a   Brunet, Merce ^e   Vinks, Alexander A ^f   Miura, Masatomo ^g   Marquet, Pierre ^b,c,d   Kuypers, Dirk R ^h   van Gelder, Teun ⁱ   Cattaneo, Dario ^j  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b INSERM   (France)

^c UNIVERSITY OF LIMOGES   (France)

^d LIMOGES UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY OF BARCELONA   (Spain)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^g AKITA UNIVERSITY HOSPITAL   (Japan)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GLUCURONOSYLTRANSFERASE 1A9; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SERUM ALBUMIN; TACROLIMUS;

AREA UNDER THE CURVE; BAYES THEOREM; BAYESIAN LEARNING; BIOEQUIVALENCE; CREATININE CLEARANCE; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG FORMULATION; DRUG MECHANISM; DRUG MONITORING; ENTERIC COATED TABLET; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE SEPSIS; HEMATEMESIS; HUMAN; HYPOALBUMINEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; NAUSEA; OUTCOME ASSESSMENT; PANCYTOPENIA; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; VOMITING;

EID: 79953699621     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2010.06.001     Document Type: Review

References (70)

1. Kuypers D.R., Le Meur Y.L., Cantarovich M., et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010, 5:341-358.
2. Staatz C.E., Tett S.E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007, 46:13-58.
3. Cattaneo D., Gaspari F., Ferrari S., et al. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant 2001, 15:402-409.
4. de Winter B.C., van Gelder T., Glander P., et al. Population pharmacokinetics of mycophenolic acid: a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. Clin Pharmacokinet 2008, 47:827-838.
5. Kuypers D.R., de Jonge H., Naesens M., et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 2008, 30:673-683.
6. van Gelder T., Le Meur Y., Shaw L.M., et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006, 28:145-154.
7. van Hest R.M., Mathot R.A., Pescovitz M.D., Gordon R., Mamelok R.D., van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006, 17:871-880.
8. Le Guellec C., Bourgoin H., Buchler M., et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet 2004, 43:253-266.
9. Naesens M., de Loor H., Vanrenterghem Y., Kuypers D.R. The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. Transplantation 2007, 84:362-373.
10. Nowak I., Shaw L.M. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995, 41:1011-1017.
11. van Gelder T., Silva H.T., de Fijter J.W., et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008, 86:1043-1051.
12. Weber L.T., Shipkova M., Armstrong V.W., et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002, 13:759-768.
13. Budde K., Bauer S., Hambach P., et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007, 7:888-898.
14. van Gelder T., Hilbrands L.B., Vanrenterghem Y., et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999, 68:261-266.
15. Cattaneo D., Cortinovis M., Baldelli S., et al. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. Clin J Am Soc Nephrol 2007, 2:1147-1155.
16. Arns W., Breuer S., Choudhury S., et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005, 19:199-206.
17. de Winter B.C., van Gelder T., Mathot R.A., et al. Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium. Ther Drug Monit 2009, 31:585-591.
18. Elbarbry F.A., Shoker A.S. Liquid chromatographic determination of mycophenolic acid and its metabolites in human kidney transplant plasma: pharmacokinetic application. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 859:276-281.
19. Atcheson B.A., Taylor P.J., Mudge D.W., et al. Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br J Clin Pharmacol 2005, 59:271-280.
20. Le Meur Y., Buchler M., Thierry A., et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007, 7:2496-2503.
21. Rupprecht K., Schmidt C., Raspe A., et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol 2009, 49:1196-1201.
22. Ting L.S., Villeneuve E., Ensom M.H. Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit 2006, 28:419-430.
23. Willis C., Taylor P.J., Salm P., Tett S.E., Pillans P.I. Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients. Ther Drug Monit 2000, 22:549-554.
24. Rousseau A., Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol 2002, 16:253-262.
25. Miura M., Satoh S., Niioka T., et al. Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients. Ther Drug Monit 2008, 30:52-59.
26. Miura M., Satoh S., Niioka T., et al. Early phase limited sampling strategy characterizing tacrolimus and mycophenolic acid pharmacokinetics adapted to the maintenance phase of renal transplant patients. Ther Drug Monit 2009, 31:467-474.
27. Staatz C.E., Duffull S.B., Kiberd B., Fraser A.D., Tett S.E. Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. Eur J Clin Pharmacol 2005, 61:507-516.
28. Premaud A., Le Meur Y., Debord J., et al. Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit 2005, 27:354-361.
29. Premaud A., Rousseau A., Le Meur Y., et al. Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients. Pharmacol Res 2009, 61:167-174.
30. van Hest R.M., van Gelder T., Vulto A.G., Shaw L.M., Mathot R.A. Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet 2009, 48:463-476.
31. Johnson H.J., Swan S.K., Heim-Duthoy K.L., Nicholls A.J., Tsina I., Tarnowski T. The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. Clin Pharmacol Ther 1998, 63:512-518.
32. Atcheson B.A., Taylor P.J., Kirkpatrick C.M., et al. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit 2004, 26:284-286.
33. Mudge D.W., Atcheson B.A., Taylor P.J., Pillans P.I., Johnson D.W. Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient. Ther Drug Monit 2004, 26:453-455.
34. Hao C., Anwei M., Bing C., et al. Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: prediction of occurrence of leukopenia. Liver Transpl 2008, 14:1165-1173.
35. Kaplan B., Gruber S.A., Nallamathou R., Katz S.M., Shaw L.M. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation 1998, 65:1127-1129.
36. Kuypers D.R., Vanrenterghem Y., Squifflet J.P., et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 2003, 25:609-622.
37. de Winter B.C., van Gelder T., Sombogaard F., Shaw L.M., van Hest R.M., Mathot R.A. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmacodyn 2009, 36:541-564.
38. Hesselink D.A., van Hest R.M., Mathot R.A., et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005, 5:987-994.
39. Cattaneo D., Merlini S., Zenoni S., et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant 2005, 5:2937-2944.
40. Baldelli S., Merlini S., Perico N., et al. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 2007, 8:1127-1141.
41. Kuypers D.R., Naesens M., Vermeire S., Vanrenterghem Y. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 2005, 78:351-361.
42. Prausa S.E., Fukuda T., Maseck D., et al. UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients. Clin Pharmacol Ther 2009, 85:495-500.
43. van Schaik R.H., van Agteren M., de Fijter J.W., et al. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther 2009, 86:319-327.
44. Miura M., Satoh S., Inoue K., et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007, 63:1161-1169.
45. Levesque E., Delage R., Benoit-Biancamano M.O., et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 2007, 81:392-400.
46. Levesque E., Benoit-Biancamano M.O., Delage R., Couture F., Guillemette C. Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers. Pharmacogenomics 2008, 9:869-879.
47. Bowalgaha K., Miners J.O. The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 2001, 52:605-609.
48. Shipkova M., Armstrong V.W., Oellerich M., Wieland E. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 2003, 25:1-16.
49. Girard H., Court M.H., Bernard O., et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 2004, 14:501-515.
50. Bernard O., Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 2004, 32:775-778.
51. Basu N.K., Kole L., Kubota S., Owens I.S. Human UDP-glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug Metab Dispos 2004, 32:768-773.
52. Picard N., Ratanasavanh D., Premaud A., Le Meur Y., Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 2005, 33:139-146.
53. Bernard O., Tojcic J., Journault K., Perusse L., Guillemette C. Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab Dispos 2006, 34:1539-1545.
54. Strassburg C.P., Oldhafer K., Manns M.P., Tukey R.H. Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 1997, 52:212-220.
55. Cheng Z., Radominska-Pandya A., Tephly T.R. Cloning and expression of human UDP-glucuronosyltransferase (UGT) 1A8. Arch Biochem Biophys 1998, 356:301-305.
56. Inoue K., Miura M., Satoh S., et al. Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Ther Drug Monit 2007, 29:299-304.
57. Kagaya H., Inoue K., Miura M., et al. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007, 63:279-288.
58. Innocenti F., Liu W., Chen P., Desai A.A., Das S., Ratain M.J. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics 2005, 15:295-301.
59. Westley I.S., Brogan L.R., Morris R.G., Evans A.M., Sallustio B.C. Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. Drug Metab Dispos 2006, 34:261-266.
60. Kobayashi M., Saitoh H., Tadano K., Takahashi Y., Hirano T. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 2004, 309:1029-1035.
61. Naesens M., Kuypers D.R., Verbeke K., Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 2006, 82:1074-1084.
62. Miura M., Kagaya H., Satoh S., et al. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit 2008, 30:559-564.
63. Arns W. Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity?. Transplant Proc 2007, 39:88-93.
64. Heller T., van Gelder T., Budde K., et al. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. Am J Transplant 2007, 7:1822-1831.
65. van Agteren M., Armstrong V.W., van Schaik R.H., et al. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism. Ther Drug Monit 2008, 30:439-444.
66. Carr S.F., Papp E., Wu J.C., Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993, 268:27286-27290.
67. Grinyo J., Vanrenterghem Y., Nashan B., et al. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int 2008, 21:879-891.
68. Sombogaard F., van Schaik R.H., Mathot R.A., et al. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. Pharmacogenet Genomics 2009, 19:626-634.
69. Wang J., Yang J.W., Zeevi A., et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther 2008, 83:711-717.
70. Glander P., Hambach P., Braun K.P., et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 2004, 4:2045-2051.